{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-TNF+therapy", "query": { "intervention": "Anti-TNF therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 129, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-TNF+therapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T13:55:09.235Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03001219", "title": "A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Anti-TNF-alpha", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "RO7123520", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2016-12-22", "completion_date": "2018-11-06", "has_results": true, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-09-09T13:55:09.235Z", "location_count": 32, "location_summary": "Anniston, Alabama • Glendale, Arizona • Mesa, Arizona + 25 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03001219" }, { "nct_id": "NCT05271318", "title": "Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Platinum-refractory Ovarian Carcinoma", "Platinum-resistant Ovarian Cancer", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Refractory Fallopian Tube Carcinoma", "Platinum-Refractory Primary Peritoneal Carcinoma", "Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin", "Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin", "Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin" ], "interventions": [ { "name": "TILT-123", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "pegylated liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "TILT Biotherapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 29, "start_date": "2022-05-17", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-09-09T13:55:09.235Z", "location_count": 2, "location_summary": "Rochester, Minnesota • New York, New York", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05271318" }, { "nct_id": "NCT01230827", "title": "A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Juvenile Idiopathic Arthritis" ], "interventions": [ { "name": "CNTO 148 (Golimumab)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 173, "start_date": "2010-12", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-04-04", "last_synced_at": "2026-09-09T13:55:09.235Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01230827" }, { "nct_id": "NCT01526057", "title": "A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "PF-05280586", "type": "BIOLOGICAL" }, { "name": "MabThera", "type": "BIOLOGICAL" }, { "name": "Rituxan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2012-03-20", "completion_date": "2014-05-07", "has_results": true, "last_update_posted_date": "2019-11-19", "last_synced_at": "2026-09-09T13:55:09.235Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01526057" }, { "nct_id": "NCT01147341", "title": "Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Cimzia", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Schiff, MD", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 37, "start_date": "2010-07", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-09-09T13:55:09.235Z", "location_count": 12, "location_summary": "Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147341" }, { "nct_id": "NCT01709578", "title": "To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "hydroxychloroquine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "sulfasalazine", "type": "DRUG" }, { "name": "leflunomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 546, "start_date": "2012-10", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2017-08-08", "last_synced_at": "2026-09-09T13:55:09.235Z", "location_count": 56, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01709578" }, { "nct_id": "NCT03646708", "title": "Response Assessment in SB CD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Small Bowel Crohn's Disease" ], "interventions": [], "intervention_types": [], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2018-05-09", "completion_date": "2027-05-30", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-09-09T13:55:09.235Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03646708" }, { "nct_id": "NCT00792233", "title": "Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Juvenile Idiopathic Arthritis" ], "interventions": [ { "name": "Withdrawal of anti-TNF therapy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "4 Years to 20 Years" }, "enrollment_count": 137, "start_date": "2009-06", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2016-04-15", "last_synced_at": "2026-09-09T13:55:09.235Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00792233" }, { "nct_id": "NCT00042406", "title": "Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Humax-CD4", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2002-03-04", "completion_date": "2003-03-31", "has_results": false, "last_update_posted_date": "2023-04-28", "last_synced_at": "2026-09-09T13:55:09.235Z", "location_count": 50, "location_summary": "Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00042406" }, { "nct_id": "NCT05014555", "title": "Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Inflammatory Bowel Diseases" ], "interventions": [ { "name": "COVID-19 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GI Alliance", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 400, "start_date": "2023-07-05", "completion_date": "2024-01", "has_results": false, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-09-09T13:55:09.235Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Baton Rouge, Louisiana • Southlake, Texas + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Southlake", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05014555" } ] }